Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Ebersberg – page 60

1 343 clinical trials in Ebersberg, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Ebersberg at a glance
1 343
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 343 trials in Ebersberg

Open in trial search

Study on Long-Term Safety of Cendakimab for Adults and Adolescents with Eosinophilic Esophagitis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cendakimab
  • Sponsor:Celgene International II S.a.r.l.

Study of LY3541860 and Meglumine Gadoterate for Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:LY3541860
  • Sponsor:Eli Lilly & Co.

Study on the Effectiveness and Safety of AVP-786 (Quinidine Sulfate and Deudextromethorphan Hydrobromide) for Treating Agitation in Alzheimer's Dementia Patients

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Quinidine Sulfate
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Seagen Inc.

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:AstraZeneca AB

Parkinson's disease

Not recruiting

Study on the Long-Term Safety of Tavapadon for Patients with Parkinson's Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tavapadon
  • Sponsor:Cerevel Therapeutics LLC

Schizophrenia

Not recruiting

Study on Long-Term Safety of Iclepertin for Patients with Schizophrenia Who Completed Previous Trials

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Iclepertin
  • Sponsor:Boehringer Ingelheim International GmbH

Systemic scleroderma

Not recruiting

Study on the Effects of Fipaxalparant in Patients with Diffuse Cutaneous Systemic Sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fipaxalparant
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Migraine+3

Not recruiting

Study Comparing Atogepant and Topiramate for Preventive Treatment in Adults with Migraine

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atogepant
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Arteriosclerosis

Not recruiting

Study on the Effect of Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease Not Adequately Managed by Current Lipid-Lowering Treatments

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obicetrapib
  • Sponsor:NewAmsterdam Pharma B.V.

Study on Tofacitinib for Patients with Early Active Axial Spondyloarthritis Who Did Not Respond to NSAIDs

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Naproxen
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Asthma

Not recruiting

Study on the Safety of CHF5993 Inhaler with HFA-152a vs. HFA-134a in Patients with Moderate to Severe Asthma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol
  • Sponsor:Chiesi Farmaceutici S.p.A.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Ebersberg

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on triple-negative breast cancer treatment, evaluating the effectiveness of combining immunotherapy with conventional chemotherapy approaches.

  • Neoadjuvant Chemotherapy Studies
  • Immunotherapy Integration
  • Event-free Survival Assessment

Research aims to enhance treatment outcomes through targeted therapeutic combinations.

02 Genetic-Based Treatment

Studies examining treatment efficacy in patients with BRCA mutations, specifically targeting high-risk HER2-negative breast cancer cases.

  • Adjuvant Therapy Development
  • Invasive Disease Management
  • Targeted Treatment Approaches

Focused on improving survival rates through genetically-informed treatment strategies.

03 Hormone Receptor Research

Investigation of advanced treatment protocols for HR+/HER2- early breast cancer, combining endocrine therapy with innovative therapeutic agents.

  • Long-term Endocrine Therapy
  • Combination Treatment Protocols
  • Disease-free Survival Studies

Evaluating enhanced treatment strategies for hormone-responsive breast cancers.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.